The Guardion Health Sciences Inc (GHSI) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered GHSI. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for GHSI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedGHSI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Guardion Health Sciences Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on GHSI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of GHSI.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Anthony Vendetti Maxim Group | Hold | Downgrade | Feb 2, 2024 | |
Edward Woo Ascendiant Capital | Buy | $0.75 | Initiates | Jul 18, 2022 |
Maxim Group | Buy | Initiates | Mar 8, 2022 |
When did it IPO
2019
Staff Count
9
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Ms. Janet Hall
Market Cap
$14.7M
In 2023, GHSI generated $12.2M in revenue, which was a increase of 10.85% from the previous year. This can be seen as a signal that GHSI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.